Table 1. Baseline characteristics by level of estimated creatinine clearance among women enrolled in HERSa
| Creatinine clearance (ml/min per 1.73 m2) | |||
|---|---|---|---|
| ≥60 (n = 1275) | 30–59 (n = 1438) | <30 (n = 44) | |
| a MI, myocardial infarction; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal angioplasty. | |||
| b P ≤ 0.05. | |||
| c P ≤ 0.01. | |||
| d P ≤ 0.001. | |||
| Age ± SD (yr) | 63 ± 6 | 70 ± 6d | 71 ± 5d |
| Race | |||
| white (%) | 88 | 90 | 73c |
| black (%) | 8 | 8 | 25d |
| other (%) | 4 | 3c | 2 |
| Untreated diabetes | 9 | 7b | 8 |
| Treated with oral agent | 10 | 8c | 23* |
| Treated with insulin | 9 | 9 | 16 |
| Hypertension (%) | 67 | 70b | 93d |
| Mean LDL cholesterol ± SD (mg/dl) | 147 ± 40 | 143 ± 36c | 149 ± 46 |
| Mean HDL cholesterol ± SD (mg/dl) | 49 ± 12 | 51 ± 14d | 51 ± 17 |
| Median lipoprotein(a) level (25th–75th percentile range) | 24 (7 to 53) | 27 (7 to 56) | 26 (8 to 60) |
| Mean triglyceride level ± SD (mmHg) | 168 ± 63 | 164 ± 63b | 190 ± 72b |
| Mean body mass index ± SD (kg/m2) | 31 ± 6 | 27 ± 5d | 28 ± 5d |
| Current smoker (%) | 16 | 11d | 21 |
| Aspirin use at baseline (%) | 80 | 78 | 57d |
| HMG-CoA reductase inhibitor use at baseline (%) | 36 | 37 | 41 |
| Estrogen progestin treatment group (%) | 51 | 49 | 48 |
| Any alcohol use in last 30 d (%) | 42 | 39 | 32 |
| Exercise | 64 | 65 | 30d |
| Average number of prior MI | 0.6 | 0.6 | 0.8b |
| Percent prior CABG | 38 | 44c | 52 |
| Percent prior PTCA | 46 | 41b | 34 |